Research Conducted by Florida Cancer Specialists & Research Institute Featured at Unique Immunotherapy Symposium

Fort Myers, Fla., December 8, 2023 – Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) was featured this week at an international symposium devoted entirely to the development and use of immunotherapies against cancer. Three FCS physician investigators are co-authors of four research studies that will be shared at the ESMO Immuno-Oncology Congress 2023 in Switzerland, a global gathering offering an advanced educational program and a platform for the latest scientific developments in this promising field.

Immunotherapy, which uses the body’s own immune system to find, target and fight many forms of cancer even at advanced stages, is one of the most promising and successful new treatment areas for cancer therapies. FCS President & Managing Physician Lucio N. Gordan, MD said, “Through our extensive clinical trials research program, FCS continues to make great strides in the advancements of these novel therapies, which are enabling the development of truly targeted treatment plans individualized for each patient’s unique genetic profile.”

The following FCS physician investigators will present full data of research results during oral or poster presentations and discussions:

Judy Wang, MD, FCS Associate Director of Drug Development, as co-author of the evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer and a Phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab.

Cesar Augusto Perez, MD, as co-author of a Phase 1/2 Study of XTX101, a Masked, Tumor-Activated Fc-enhanced 490 Anti-CTLA-4, in Patients with Advanced Solid Tumors and as co-author of a Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC).

Alexander Philipovskiy, MD, PhD, as co-author of a randomized, open-label, Phase 2 study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer.

“We are proud to be contributing so significantly to the emerging evidence and research within the fast-developing field of cancer immunotherapies that are contributing to game-changing positive outcomes for patients,” said Gustavo A. Fonseca, MD, FACP, FCS Director of Clinical Research.

ESMO, the European Society for Medical Oncology represents more than 34,000 oncology professionals in 170 countries. ESMO’s core mission is to improve the quality of cancer care, and to provide education on the best practices and latest advances in oncology and promote equal access to optimal cancer care for all patients.

Details from the ESMO-IO program and a full list of abstracts can be found here.